Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

BPC-157

A synthetic 15-amino-acid peptide with extensive animal literature, sparse and methodologically weak human evidence, and no verified approved medicine in the Canadian or U.S. sources reviewed.

Aliases reviewed
Body protection compound 157, BPC 157, PL 14736, PLD-116
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedA few small, exploratory human reports.
Animal/cell
Not rated
Approved medicine
None foundScope: the Canadian and U.S. sources reviewed.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A rat tendon can answer a rat-tendon question. It cannot tell us whether a vial is suitable for a person—or even whether that vial contains the studied material.”

BPC-157 attracts bold recovery claims. The careful version is narrower: researchers have reported effects in several injury models, while the human evidence remains too small and incomplete to establish benefit or characterize safety.

Identity and established aliases

BPC-157 is described as a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV. Historical papers also use development codes PL 14736 and PLD-116. FDA's 2026 review treated the free base and acetate as distinct bulk drug substances and noted incomplete physicochemical characterization and inconsistent naming.

The name is associated with a fragment described from a gastric protective protein, but the molecular target has not been established. A shared name does not establish that different salts, formulations, or catalogue materials are equivalent.

Why researchers study it

Preclinical researchers have examined gastrointestinal injury, fistulas, liver injury, angiogenesis, and musculoskeletal repair. Proposed explanations include changes in growth-factor signalling, inflammatory mediators, nitric-oxide pathways, and blood-vessel formation. FDA concluded that dose-response relationships and molecular targets remain unresolved, so these are proposed mechanisms rather than a settled biological role.

Approved medicines and investigational uses

No BPC-157 active-ingredient record was returned by Health Canada's Drug Product Database under the reviewed name on the access date. FDA's 2026 evaluation stated that neither BPC-157 free base nor acetate is a component of an FDA-approved drug. These are jurisdiction-specific searches, not proof about every country or every spelling.

Human investigation has included rectal formulations in exploratory ulcerative-colitis work, intra-articular administration described in a retrospective knee-pain chart review, and a two-person intravenous safety pilot. These routes, formulations, populations, and outcomes are not interchangeable.

What human studies show

FDA identified a small exploratory ulcerative-colitis study reported only in limited form and found the available information insufficient to support effectiveness. Two rectal-enema studies supplied little safety detail and did not establish long-term safety or systemic pharmacokinetics.

A retrospective clinic report contacted 16 people after knee injections; it had no control group, used subjective telephone follow-up, mixed BPC-157 alone with a BPC-157/thymosin-beta-4 combination, and did not use validated function or quality-of-life measures. It can generate hypotheses, not establish treatment effect.

A 2025 pilot monitored two adults after intravenous infusions and reported no measured short-term adverse effects. Both participants had previously received intravenous BPC-157, the sample was two, and the study was not designed to measure efficacy or uncommon and delayed harms.

What cells and animal studies show

Rat studies reported changes in tendon mechanics, histology, and functional measures after experimentally transected Achilles tendons. Other rat and cell work reported VEGFR2-related signalling and angiogenesis-associated measures. These experiments used defined laboratory preparations and injury models; they do not establish clinical recovery, a safe human route, or a useful human formulation.

Popular claims include faster recovery from tendon, ligament, muscle, joint, and gastrointestinal problems. The reviewed literature does not establish those broad outcomes in people. The most positive human musculoskeletal report is uncontrolled and retrospective; the stronger-looking repair findings are preclinical.

What remains uncertain

Human absorption, metabolism, dose-response relationships, long-term safety, carcinogenicity, reproductive effects, and clinically meaningful benefits remain unresolved. FDA also identified possible immunogenicity from aggregation or peptide-related impurities and noted animal clotting and liver-associated signals whose human relevance is unknown.

Spontaneous adverse-event reports included injection-site reaction, shortness of breath, and pigmentation changes, but missing information, other substances, and mixed products prevent causal attribution. Absence of a signal in tiny studies is not evidence that a risk is absent.

NOT SCIENTIFIC EVIDENCE

Anecdotal reports

These are attributed accounts of why someone said they used this compound, from published reporting. A report shows only that someone said something. It does not show that the compound works, that it is safe, how often it is used, or that one thing caused another, and it is not a recommendation. These reports do not count toward the evidence summary above.

  1. Anecdotal report · news report quoting individuals

    Peptides for injury recovery: medical miracle or medical risk? (external link)

    FOX Carolina (by Kari Beal) ·

    Reported purpose
    A man named in a FOX Carolina report, who had sprained his ankle and partially torn his Achilles tendon, was described as wondering if he could heal faster when he asked his doctor about peptides; the article says he then started BPC-157.
    Compound actually discussed
    BPC-157, named by the article. The article says his clinician prescribed him both BPC-157 and TB-500 but states only that he was taking BPC-157. No salt, formulation or product identity is given.
    What this source can and cannot establish
    Only that a local TV news report exists in which a named person described starting BPC-157 after an ankle sprain and partial Achilles tear and reported that he recovered. It does not establish effectiveness, safety, causality, typical use or how common this is.
    What the scientific sources say
    The profile's tendon findings come from a surgical rat model, which cannot establish human clinical recovery or product equivalence. The most positive human musculoskeletal report among the profile's sources is an uncontrolled retrospective chart review of 16 contacted knee-pain patients, with non-validated telephone outcomes and mixed interventions; it can generate hypotheses but cannot establish a treatment effect. FDA's May 2026 advisory-committee briefing evaluation found insufficient clinical information to characterize BPC-157's safety profile, found the limited ulcerative-colitis data inadequate to support effectiveness, and stated that neither BPC-157 free base nor acetate is a component of an FDA-approved drug; it is a briefing, not a final determination. Health Canada's Drug Product Database returned no BPC-157 active-ingredient record under that name. The reviewed sources do not establish faster tendon or ligament recovery in people.Sources: BPC 157 and healing of transected rat Achilles tendon; Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain; FDA 2026 evaluation of BPC-157-related bulk drug substances; Health Canada DPD active-ingredient search: BPC-157.
    Uncertainties
    This is one self-reported account. His reported recovery may also reflect physical therapy and the natural healing course. The article says the clinician quoted in the story prescribed the peptides to him, so the story's medical commentary comes from his prescriber. The physical therapist's reported comparison is second-hand. The article does not confirm whether TB-500 was also used, or the identity or quality of the material. The article itself states that most research on these compounds comes from animal trials, not human studies.

    Source accuracy and wording independently reviewed Oct 28, 2026.

  2. Anecdotal report · news report of a records analysis

    Use of untested 'Wolverine' peptide backed by US Health Secretary Kennedy on the rise, study finds (external link)

    Reuters (by Nancy Lapid), republished by the Hawaii Tribune-Herald ·

    Reported purpose
    A Reuters report on a not-yet-peer-reviewed analysis of more than 15 million medical records said that, among the 644 patients whose clinical notes documented a reason, recorded reasons for BPC-157 use ranged from sports injuries and chronic pain to gastrointestinal disorders, with pain or gastrointestinal symptoms the most often documented reasons for starting.
    Compound actually discussed
    BPC-157, as clinicians wrote it in medical-record notes. No salt, formulation or product identity is given.
    What this source can and cannot establish
    This is a news report of an aggregate, clinician-documented records analysis, not a first-person user account. It establishes only that the report describes those documented reasons. It does not establish effectiveness, safety, causality or how widespread use is; the study leader is reported as saying the true scale of use is unknown.
    Where the numbers come from
    The counts are the report's own and come from a non-random records sample: reasons were documented for 644 of 1,039 identified patients. They describe that sample only, not how widespread use is.
    What the scientific sources say
    For gastrointestinal uses, FDA's May 2026 evaluation, prepared for its July 2026 compounding advisory committee, found that a single small exploratory ulcerative-colitis study, reported only as a meeting abstract, was insufficient to support effectiveness, and that the rectal-enema studies gave little safety detail. For musculoskeletal uses, the most positive human report among the profile's sources is an uncontrolled retrospective chart review of 16 contacted knee-pain patients, and the tendon-repair findings come from rat models. The reviewed literature does not establish broad recovery, joint or gastrointestinal outcomes in people.Sources: FDA 2026 evaluation of BPC-157-related bulk drug substances; Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain; BPC 157 and healing of transected rat Achilles tendon.
    Uncertainties
    This is a second-hand report of an analysis that the article neither names nor links; the underlying preprint was not reviewed. These are clinician-documented reasons in records, not a survey of users, and no individual user is quoted. The report says reasons for use were documented for 644 of the 1,039 identified patients and that responses to treatment were recorded for only about one-third of patients. The report also says a July 2026 panel of FDA advisers voted to allow pharmacy compounding of BPC-157; that vote is advisory, and FDA's May 2026 evaluation, prepared for that meeting, is not FDA's final position.

    Source accuracy and wording independently reviewed Oct 28, 2026.

What this profile is—and is not

Evidence review complete for this edition; conclusions should be revisited if full human trial reports or a regulatory decision appear.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.